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Abstract  
Aims: There are several epidemiological studies on the association between statins and 
incident diabetes, but most of them lack details. In this study, we aimed to investigate the 
association of statin use with glycaemic traits and incident type 2 diabetes. 
Methods: Using the prospective population-based Rotterdam Study, we included 9,535 
individuals free from diabetes at baseline (>45 years) during the study period between 1997 
and 2012. Linear regression analysis was applied to examine the cross-sectional associations 
between statin use and glycaemic traits including fasting blood serum of glucose and insulin 
concentrations, and insulin resistance. In a longitudinal follow-up study, we applied a Cox 
regression analysis to determine adjusted hazard ratios (HR) for incident type 2 diabetes in 
new users of statins.  
Results. The mean age at baseline was 64.3±10.1 year and 41.7% were men. In the fully 
adjusted model, compared to never users of statins, baseline use of statins was associated 
with higher concentrations of serum fasting insulin (β, 0.07; 95% CI: 0.02-0.13) and insulin 
resistance (β, 0.09; 95% CI: 0.03-0.14). Ever use of statins was associated with a 38% higher 
risk of incident type 2 diabetes (HR, 1.38; 95% CI: 1.09-1.74). This risk was more prominent 
in subjects with impaired glucose homeostasis and in overweight/obese individuals. 
Conclusions: Individuals using statins may be at higher risk for hyperglycaemia, insulin 
resistance and eventually type 2 diabetes. Rigorous preventive strategies such as glucose 
control and weight reduction in patients when initiating statin therapy might help minimizing 
the risk of diabetes. 
Key words: Statins, impaired fasting glucose, insulin resistance, type 2 diabetes mellitus. 
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What is already known about this subject  
 Several observational studies and trials have already reported an increased risk of 
incident type 2 diabetes in subjects treated with statins; however, most of them lack 
details. 
 The increased risk of incident type 2 diabetes associated with statin use is much 
higher (44%) in observational studies compared with trials (9–13%). 
 There are limited studies on the association of statin use with glycemic traits.  
What this study adds  
Using fully adjusted regression models (adjusted for baseline/post-baseline measurements of 
potential risk factors): 
 Compared to never statin users, baseline use of statin was associated with higher 
concentrations of serum fasting insulin (β, 0.07; 95% CI: 0.02-0.13) and insulin 
resistance (β, 0.09; 95% CI: 0.03-0.14).  
 Ever use of statins was associated with a 38% higher risk of incident type 2 diabetes 
(HR, 1.38; 95% CI: 1.09-1.74).  
 This risk was more prominent in subjects with impaired glucose homeostasis and in 
overweight/obese individuals. 
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Introduction 
Although it is well known that statins significantly reduce the risk of cardiovascular disease 
(CVD) and CVD related mortality [1, 2], statin therapy may lead to increased risk of type 2 
diabetes [3, 4]. A recent meta-analysis of 29 randomized clinical trials (RCTs) reported a 
12% significantly increased risk of developing type 2 diabetes in the treated arm of statin 
therapy [5]. However, use under everyday circumstances differs from use in a clinical trial 
setting with its homogeneous population and short follow-up [6]. Experimental studies 
suggest that statins may have a diabetogenic effect through beta-cell dysfunction and glucose 
and insulin secretion/sensitivity [7, 8]; however, the data linking statins with glucose and 
insulin resistance to show the underlying mechanisms is limited. The literature so far on 
statin use and the risk of developing type 2 diabetes has been limited by several drawbacks: i) 
underestimated cases of incident type 2 diabetes due to the inclusion of questionnaire-based 
data, ii) short follow-up time not adequately taking into account the long-term effects of 
statins, and iii) lack of a direct comparison between different statin types, dosages and 
duration of use with respect to diabetes-related outcomes [3, 9, 10].  
We hypothesized that statins have influence on serum blood glucose and insulin 
concentrations and insulin resistance, and lead to hyperglycaemia and hyperinsulinemia as 
early markers of type 2 diabetes. In this study, exploring different aspects of statin therapy 
including type, dosages and durations of use, our objective was to assess the population-
based association of statins with concentrations of serum fasting glucose and insulin, insulin 
resistance, and incident type 2 diabetes.   
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Methods 
Study setting. The Rotterdam Study is a prospective population-based cohort study in 
Ommoord, a district of Rotterdam, the Netherlands. The design of the Rotterdam Study has 
been described in more detail elsewhere [11]. Briefly, in 1989 all residents aged 45 years or 
older within the well-defined study area were invited to participate, of whom 78% (7,983 out 
of 10,275) agreed. In 2000, an additional 3,011 participants were enrolled (RS-II), consisting 
of all persons living in the study district who had become 55 years of age. A second extension 
of the cohort was initiated in 2006, in which 3,932 participants aged 45 years or older were 
included (RSIII). The Rotterdam Study has been approved by the medical ethics committee 
according to the Population Screening Act: Rotterdam Study, executed by the Ministry of 
Health, Welfare and Sports of the Netherlands. All participants in the present analysis 
provided written informed consent to participate and to obtain information from their 
physicians. 
Study Design. We performed two analyses. First, a cross-sectional analysis to test the 
association between statins and glycaemic traits and second, a longitudinal follow-up study to 
test the association of statins with incident type 2 diabetes. 
Population for analysis. The present study used data from the third visit of the first cohort, 
RSI-3 (March 1997- December 1999) and the baseline examinations of the second cohort, 
RSII-1 (February 2000-December 2001) and third cohort, RSIII-1 (February 2006-December 
2008) (Supplementary Figure S1). To study the association between statins and the outcomes 
of interest, we excluded prevalent type 2 diabetes cases at baseline (n=1,565), and included 
only participants with available data on statin use and baseline glycaemic values (n=9,535). 
To study the association of statins with incident type 2 diabetes, patients who used statins at 
baseline and prevalent cases of cardiovascular diseases (n=691) were also excluded from the 
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analysis. The end of follow-up for incidence of type 2 diabetes was January 1st 2012 
(Supplementary figure 1). 
Exposure measurement. All community pharmacies in the Rotterdam Study area store all 
information on drug dispensing on one common computer network. Information on statin 
treatment was obtained from the dispensing data using the Anatomical Therapeutical 
Chemical code (ATC code) (Supplementary table S1). On the baseline date, an individual 
was considered as current statin user if this date fell within a prescription episode. During 
follow-up, each participant was classified into one of the following mutually exclusive 
categories on the event date of type 2 diabetes (in non-cases at the same day of follow-up): 
‘current use’, ‘past use’, and ‘never use’. If the outcome measurement occurred within a 
prescription episode of statins, a person was classified as a current user and stratified by statin 
duration into three mutually exclusive groups: <30 days; 31-365 days; and >365 days. If the 
participant had previously used statins but was no longer a current user on the event date, this 
was defined as past use. If the participant had not used statin during the study period, this was 
defined as ‘never use’ whereas any use (‘current’ or ‘past use’) during the study period was 
defined as ‘ever use’.  
Outcomes’ measurement 
Fasting serum glucose concentrations, insulin and insulin resistance. Serum glucose 
(mmol/l) and insulin (pmol/l) concentrations were measured at the research centre after an 
overnight fast. For collecting serum specimens from the whole blood, fasting blood samples 
were centrifuged at 4 °C at 3500 rpm, then serums were immediately frozen at – 140 °C and 
stored at −80°C in the clinical chemistry laboratory at Erasmus Medical Centre in Rotterdam. 
Glucose concentration was measured using glucose hexokinase method within 1 week after 
sampling [12] and insulin concentration by metric assay (Biosource Diagnostics, Camarillo, 
CA). Homeostasis model assessment-insulin resistance (HOMA-IR) index as a surrogate 
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marker for the degree of insulin resistance was calculated by the following formula: (fasting 
serum insulin (mU/l) × fasting serum glucose (mmol/l))/22.5 [13]. 
Type 2 diabetes diagnosis. From the date of baseline centre visit and during follow-up, first 
incident type 2 diabetes cases were identified through active follow-up and according to 
general practitioners’ records, hospital discharge letters, and glucose measurements. Type 2 
diabetes was defined as a fasting serum glucose concentration of ≥7.0 mmol/l or a non-
fasting serum glucose concentration of ≥11.1 mmol/l (in case fasting serum samples were not 
available), or the use of blood glucose-lowering medications [14].  
Covariates assessment. At baseline and during follow-up, information was obtained on 
individuals’ characteristics, health status, clinical data including medical and medication 
history, and behavioural/lifestyle factors. Physical activity levels assessed using the 
Longitudinal Aging Study Amsterdam Physical Activity Questionnaire expressed in MET-
h/week [15] and defined as number of hours per week that participants spent in each activity 
in the past year. Body mass index (BMI) was calculated as body weight (in kilogram) divided 
by the square of body height (in metres) included as a continuous variable. Baseline and 
postbaseline values (at the closest time to diabetes diagnosis) for BMIs were categorized as 
overweight/obesity defined as BMI ≥25 kg/m
2 
versus normal (BMI<25 kg/m
2
). Hypertension 
was defined as an average value (of two measurements) of ≥140 mmHg for systolic- and ≥90 
mmHg for diastolic blood pressure after two measurements and/or a current prescription for an 
antihypertensive agent. Serum total cholesterol (TC) (mmol/l), high density lipoproteins-
cholesterol (HDL-C) (mmol/l), and triglycerides (TG) (mmol/l) were all measured on the 
COBAS 8000 Modular Analyzer (Roche Diagnostics GmbH). We calculated low density 
lipoproteins-cholesterol (LDL-C) levels (mmol/l) indirectly from the measurements of TC, 
HDL-C and TG using the Friedewald equation (TC minus HDL-C minus TG/5) [16]. A family 
history of diabetes was defined as having a parent, sibling, or both with type 2 diabetes; the 
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information on family history of diabetes was collected during home visits at RSI and RSII. 
All biochemical variables were assessed in serum samples taken after an overnight fasting.  
Statistical analyses. For comparison of baseline characteristics between statin users and 
never users in the first analysis, we used chi-square statistics for dichotomous variables and 
independent sample t-tests for normally distributed continuous variables. To achieve a 
symmetric distribution, non-normally distributed data on BMI, TG, fasting serum insulin 
concentrations and the HOMA-IR index were natural log transformed. Univariable and 
multivariable linear regression analyses were used to study the association between statins 
and glycaemic traits including serum fasting glucose and insulin concentrations and HOMA-
IR. Correlation coefficients to identify the magnitude of the linear association between serum 
fasting glucose and insulin concentrations and the HOMA-IR index were studied with the 
Pearson test.  
 To study the association between statin use as a time-varying exposure during the 
follow-up and incident type 2 diabetes, we used multiple Cox regression analyses [17]. The 
association was estimated by calculating hazard ratio (HR) and 95% confidence intervals 
(CI). All analyses show the effect estimates for ever, past or current versus never statin users 
as the reference group. Among ever statin users, in subgroup analyses, we analysed the risk 
of different outcomes in relation to statin type, dose, and duration of use.  
 Because statins are often started in patients with type 2 diabetes, we performed two 
subgroup analyses to avoid confounding by indication. First, we subtracted one year from the 
event date in type 2 diabetes cases (in non-cases one year from the same date of follow-up) 
and studied the association with statin use until that date (cumulative statin use). Second, for 
those participants for whom we had an incident date of impaired fasting glucose (defined as a 
serum fasting glucose concentration between 6.1 and 6.9 mmol/l), we studied the association 
between statin use and incident impaired fasting glucose during follow-up.  
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All regression analyses were adjusted for potential baseline confounding factors using 
two models including: model 1 adjusted for age and gender, cohort (RSI, II and III), smoking 
status, alcohol consumption, physical activity, and education level, and model 2 additionally 
adjusted for BMI and hypertension.  
Sensitivity analyses for the association between statin and incident type 2 diabetes. In a 
sensitivity analysis, we examined the association between statins and risk of incident type 2 
diabetes only in a subset of patients (n=6,787) with normal baseline fasting glucose 
concentrations <6.1 mmol/l by excluding cases of impaired fasting glucose cases (n=2,748). 
To exclude the likelihood of residual confounding, the association was further adjusted by 
postbaseline values of BMI. To explore if biological risk factors could partly explain this 
association, the model 2 was further adjusted for (i) TC, or (ii) HDL-C, LDL-C and TG. In 
another sensitivity analysis, the model 2 was further adjusted for family history of diabetes, 
and use of proton pump inhibitors (PPIs) at baseline [18]. To test whether the association 
between statins and incident type 2 diabetes would be explained by the potential intermediate 
factors, serum glucose and insulin concentrations were added to the model 2. Using stratified 
analyses, we also checked the potential effect modification from age at baseline (≤65 years 
versus >65 years), gender and BMI at baseline (overweight/obese (BMI>25) versus normal 
BMI individuals). We further tested an interaction between statin ever use and serum fasting 
glucose concentrations using a Cox regression model containing statin ever use, glucose 
concentrations and the product term of statin ever multiplied by glucose concentrations 
adjusted for potential confounders in the model 1.  
A p-value of 0.05 was used to assess the significance of main effect associations. All 
statistical analyses were carried out using IBM SPSS Statistics software (version 24.0, 
Chicago, IL, USA). 
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Results 
Baseline characteristics. A total of 9,535 diabetes-free individuals at baseline were included 
after exclusion of patients with prevalent type 2 diabetes (Table 1). The median follow-up for 
the entire study population was 4 years (a follow-up of up to 15 years.) The mean age at 
baseline was 64.3±10.1 years and the majority of patients included in this study were females 
(58.3%). 64.5% of individuals at baseline were overweight/obese. Median serum fasting 
glucose, insulin concentrations and HOMA-IR index (interquartile range (IQR)) were 5.4 
(5.0-5.8), 67.0 (46.0-97.0), and 2.3 (1.5-3.4), respectively.  
Characteristics of the baseline statin users and never users are shown in Table 1. 
Compared to never users, statin users had significantly higher BMIs, TGs, fasting serum 
glucose and insulin concentrations and insulin resistance and higher prevalence rates of 
hypertension. Statin users had significantly lower TC, HDL-C and LDL-C as compared to 
never users. Serum glucose concentrations were weakly but significantly (p-value<0.001) 
correlated with both (ln) insulin concentrations (r=0.14) and (ln) HOMA-IR (r=0.25). 
After excluding patients who used statins at baseline (n=968), the remaining study 
participants were subsequently followed for a period up to 15 years for incident type 2 
diabetes. There were 716 cases of incident type 2 diabetes. In approximately 12.4% of the 
study population, statins were used during follow-up. In the majority of current statin users, 
the duration of use was longer than 365 days (75.5%). The most frequently dispensed statins 
were simvastatin (57.0%), atorvastatin (25.5%), and pravastatin (10.3%).  
The association of statin use with glycaemic traits. As shown in Table 2, in a cross-
sectional analysis, baseline statin use was statistically significantly associated with increased 
serum fasting insulin concentrations (β, 0.07; 95%CI: 0.02-0.13) and HOMA-IR index (β, 
0.09; 95%CI: 0.03-0.14). However, the association with serum fasting glucose concentrations 
was no longer significant after adding BMI and hypertension to the model 1 (β, 0.08; 95%CI: 
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-0.03-0.18). Subgroup multiple linear regression analyses showed no role of statin type and 
dosage on these associations (Table 2). 
The association of statin use with incident type 2 diabetes. In a longitudinal follow-up 
study, compared with never statin users, ever statin use was associated with incident type 2 
diabetes (crude HR, 1.64; 95%CI: 1.37-1.97). The observed association remained statistically 
significant even after adjusting for a range of potential confounders; model 2: HR, 1.38; 
95%CI: 1.09-1.74 (Table 3). Current but not past use of statins was associated with a greater 
risk of type 2 diabetes; model 2: HR, 1.52; 95%CI: 1.15-2.00 vs. HR, 1.18; 95%CI: 0.83-
1.67.  
Among ever statin users, no statistically significant effect of statin type and dosage on 
risk of incident type 2 diabetes was found. However, we found a significant association of 
statin duration with incident type 2 diabetes in which longer duration of statin use was 
associated with a statistically significantly increased risk of incident type 2 diabetes (Table 
3). 
Subgroup analyses  
The association of cumulative statin use with incident type 2 diabetes. In a fully adjusted 
model, cumulative exposure to statins was associated with a 35% higher risk of type 2 
diabetes (HR, 1.35; 95% CI: 1.01-1.82). Among statin users, statin dose did not modify the 
association; HR, 1.12; 95% CI: 0.87-1.44.  
The association of cumulative statins with incident impaired fasting glucose. In a Cox 
regression analysis, cumulative statin use was associated with a 9% higher risk of incident 
impaired fasting glucose; HR, 1.09; 95% CI: 1.08-1.10 after adjusting for multiple 
confounders (model 2). Among statin users, in a fully adjusted model, the association 
between statin dose and incident impaired fasting glucose was statistically significant in 
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which higher dosages were related to an increased risk of incident impaired fasting glucose; 
HR, 2.34; 95% CI: 2.32-2.36.  
Sensitivity analyses for the association between statin use and incident type 2 diabetes 
In a series of sensitivity analyses, when we excluded cases with impaired fasting glucose at 
baseline, the positive association did not change (crude HR, 1.58; 95% CI: 1.23-2.04); 
however, when we added BMI and hypertension to the model 1, the association was not 
statistically significant anymore (HR, 1.28; 95% CI: 1.00-1.76). Using postbaseline values for 
BMIs did not change the effect estimates. Further adjustment for TC, PPIs, fasting serum 
glucose and insulin concentrations did not affect the association (Table 4). Substituting TC 
with other blood lipids (HDL-C, LDL-C and TG) attenuated the observed associations. 
Stratification by age resulted in a statistically significant association only in individuals >65 
years (HR, 1.36; 95% CI: 1.02-1.83) but not in those younger than 65 years (HR, 1.25; 95% 
CI: 0.85-1.84). In gender-stratified analyses, the association between statin use and risk of 
incident type 2 diabetes was only statistically significant in males (HR, 1.52; 95% CI: 1.07-
2.16) but not in females (HR, 1.28; 95% CI: 0.93-1.74). When we stratified the analysis by 
baseline BMI, our findings showed a statistically significant association only in a subset of 
overweight/obese subjects (HR, 1.42; 95% CI: 1.10-1.83) but not in those with normal BMI 
(HR, 1.18; 95% CI: 0.69-2.02). The interaction term of statin ever use with serum fasting 
glucose concentrations was highly significant exerting the highest odds of incident type 2 
diabetes (HR, 3.51; 95% CI: 2.51-4.91).  
 
Discussion 
To the best of our knowledge, this is the first detailed population-based study to show the 
effect of statin use on incident type 2 diabetes in those free from diabetes at baseline. At 
baseline, statin use was associated with elevated values for several glycaemic traits. After 
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excluding these baseline statin users, new ever statin users during a follow-up of up to 15 
years showed a 38% increased risk of incident type 2 diabetes independent of statin type and 
dosage. All observed associations between statin use and incident type 2 diabetes remained 
significant even after adjusting for several potential risk factors for diabetes, e.g. age, 
physical activity and education level. However, there was a steep decrease in the effect 
estimates corresponding to the adjusted models. 
Impaired glycaemic traits are important hallmarks of incident diabetes in which 
impaired glucose metabolism and decreased insulin sensitivity are the two major 
pathophysiological disturbances required for the conversion to overt type 2 diabetes [19]. 
Currently, limited evidence is available concerning the impact of statin use on glycaemic 
traits [20, 21]. Elevated baseline serum glucose and insulin concentrations might be explained 
by a diabetogenic effect of statins. However, conclusions from previous studies on this effect 
is inconsistent [22-24]. Theoretically, some potential underlying mechanisms for this effect in 
diabetes-free individuals consist of i) decreased insulin-mediated cellular glucose uptake 
leading to glucose intolerance, ii) decreased isoprenoids synthesis which causes 
downregulation of glucose transporter 4 and leads to hyperglycaemia and hyperinsulinemia, 
and iii) reduced factors such as coenzyme Q10, farnesyl pyrophosphate, and dolichol leading 
to altered insulin secretion/resistance [25-28]. Since the association of statin use and serum 
fasting glucose concentrations was no longer significant after including BMI and 
hypertension, our finding suggests that the association between statins and diabetes could be 
through insulin secretion/resistance.  
In our study, the significantly higher risk of incident type 2 diabetes among statin 
users confirms and extends the results of previous studies [6, 24, 29]. Several observational 
studies and RCTs have already reported an increased risk of incident type 2 diabetes in 
subjects treated with statins; where the increased risk reported by observational studies is 
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much higher (44%) compared with RCTs (9–13%) [6, 24]. Discrepant results might be 
explained by the much longer follow-up time in observational studies than in RCTs and a 
relatively less healthy population as trials preferably enrol participants without 
multimorbidity. Longer time could result in an increased probability of developing adverse 
drug events such as diabetes [29]. According to the findings of a previous study including 
over 2 million subjects in the UK, the statin-associated diabetes risk (HR=1.22) over a period 
of 3 years was increased with longer statin duration in which the strongest significant 
association was observed when patients were followed-up for 15–20 years (HR=3.63) [30]. 
The magnitude of the association between statins and incident type 2 diabetes is also partly 
dependent on different confounders such as lipid profile and family history of diabetes [31]. 
In the 3 large RCTs, baseline fasting glucose concentrations and features of the metabolic 
syndrome e.g. TG were shown as predictive factors of incident type 2 diabetes among statin 
users [32]. Similarly, we showed that the association between statin therapy and incident type 
2 diabetes was partly dependent on lipid profiles including HDL-C, LDL-C and TG, though, 
independent of several diabetes risk factors such as hypertension. Moreover, our result of the 
interaction between statin use and serum fasting glucose concentrations was highly 
significant implying the greatest statin-associated diabetes risk in presence of baseline 
impaired glucose concentrations. Our finding here is consistent with the results of JUPITER 
trial where the majority of statin users who developed diabetes during 5 years of follow-up 
had already impaired fasting glucose. However, this study was restricted to rosuvastatin at a 
single dosage of 20 mg daily [33].  
In our study, the majority of patients were on lipid-soluble statins (simvastatin, 
atorvastatin and fluvastatin) while the number of patients on water-soluble statins 
(pravastatin) was low (10.3%). Therefore, due to different actions of specific molecules of 
statins on insulin resistance and metabolic risk profiles, further studies are required. Our 
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findings concerning a significantly increased risk of incident type 2 diabetes independent of 
statin types and dosages are in line with a previous meta-analysis [34]. To date, limited 
evidence suggests that different statin therapy including different types, dose and duration 
might exert distinct effects on statin related outcomes and the results reported by previous 
studies are conflicting [6, 34]. In line with our hypothesis of a cumulative effect of statins on 
impaired glucose and insulin resistance, the risk of incident diabetes was significantly higher 
in intermediate (31-365 days)- and long-term (>365 days) users of statins.  
We showed a significantly increased risk of statin-related type 2 diabetes only among 
overweight/obese but not in individuals with a normal BMI. Given the concern that BMI 
values above normal and dyslipidaemia are both associated with the onset of type 2 diabetes 
[35], it is important to focus on more effective prevention in individuals with a high risk 
taking this medication. This could also help improving their lipid profile and thereby 
reducing the risk of cardiovascular diseases. 
Our study has some strengths and limitations. First, the population-based and 
prospectively gathered information on disease outcome make selection- and information bias 
unlikely. The long follow-up, the availability of data on statin type, dose and duration of use 
along with the use of a series of adjusted regression models with a broad range of potential 
confounders are among the most important strengths in this study. Moreover, we were able to 
provide a comprehensive overview of the associations between statins and glycaemic traits 
and incident type 2 diabetes. However, our study has some potential limitations that should 
be acknowledged. Most importantly, to study the association between statins and incident 
type 2 diabetes, we excluded prevalent type 2 diabetes cases at baseline (n=1,565), and 
included only participants with normal fasting glucose levels (<6.1 mmol/l) who were not on 
hypoglycaemic medication. Unfortunately, we did not have data on HbA1c at baseline, a 
marker with the ability of reflecting the long-term glycemic history. Also, the association 
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between statins and type 2 diabetes could be caused by reverse causation in which high risk 
individuals e.g. patients with obesity and fatty liver were prescribed statins to prevent CVD. 
However, to decrease the effect of reverse causality on our findings, we performed two 
subgroup analyses including the associations of type 2 diabetes with cumulative statin use 
until one year before diabetes and an impaired fasting glucose, where the results still showed 
significant associations. Cumulative statin users during follow-up showed a 9% increased risk 
of incident impaired fasting glucose in which the magnitude of increased risk was directly 
proportional to the statin dosage. Though, we were able to adjust the associations for many 
measured confounding variables, the possibility remains that some factors e.g. genetic factors 
which we have not measured still modify the associations  [36]. Additionally, compared with 
never statin users, patients treated with statins tend to be sicker and are more prone to 
enhanced glucose and insulin concentrations, and to eventually developing diabetes [37]. We 
cannot rule out the effect of detection bias in our study in which individuals treated with 
statins are more likely to be clinically evaluated. Finally, since our study included a 
population consisting of roughly 95% Caucasian ethnicity and race might be an important 
factor for the association between statin use and susceptibility of diabetes, our findings 
cannot be easily generalized to other populations. 
In summary, using multiple subgroup and sensitivity analyses, we found a consistent 
significant association between statin use and incident type 2 diabetes. Our analysis also 
highlights the greatest effect of statins in presence of hyperglycaemia and overweight/obesity. 
This suggests that it is necessary to take statin diabetogenicity into consideration in clinical 
practice when statin is indicated, emphasising the concomitant need for dietary measures and 
exercise. 
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Table 1. Baseline characteristics of the study population 
 Total (n=9,535) 
Statin users 
(n=968) 
Never statin 
users (n=8,567) 
P-
value 
Age, years, mean ±SD 64.3±10.1 64.9±8.2 64.3±10.2 0.04 
Gender (male), n (%) 3977 (41.7) 481 (49.7) 3496 (40.8) <0.001 
BMI, kg/m
2
, mean ±SD 27.0±4.1 27.5±3.9 26.9±4.1 <0.001 
Family history of diabetes, n (%) 524 (8.7) 53 (5.5) 471 (5.5) 0.98 
Hypertension, n (%) 3472 (36.5) 651 (67.3) 2821 (32.9) <0.001 
Total cholesterol, mmol/l, median (IQR) 5.7 (5.1-6.4) 5.1 (4.4-5.7) 5.8 (5.2-6.5) <0.001 
HDL-C, mmol/l, median (IQR) 1.4 (1.1-1.7) 1.3 (1.1-1.5) 1.4 (1.2-1.7) <0.001 
LDL-C, mmol/l, median (IQR) 4.0 (3.4-4.6) 3.4 (2.8-3.9) 4.1 (3.5-4.7) <0.001 
Triglycerides, mmol/l, median (IQR) 1.3 (1.0-1.8) 1.5 (1.1-2.1) 1.3 (0.97-1.7) <0.001 
Physical activity, MET-h/week, mean 
±SD 
75.6±49.6 75.4±47.2 75.7±49.8 0.44 
Education status (High), n (%) 1717 (18.0) 153 (15.8) 1564 (18.3) 0.05 
Smoking status (ever), n (%) 2040 (21.4) 222 (22.9) 1818 (21.2) 0.28 
Alcohol consumption (ever), n (%) 5443 (57.1) 539 (55.7) 4904 (57.2) 0.32 
Glucose, mmol/l, median, IQR 5.4 (5.0-5.8) 5.5 (5.1-5.9) 5.4 (5.0-5.8) 0.02 
Insulin, pmol/l, median, IQR 67.0 (46.0-97.0) 78.0 (54.0-115.0) 66.0 (46.0-96.0) <0.001 
HOMA-IR index, median, IQR 2.3 (1.5-3.4) 2.7 (1.8-4.1) 2.3 (1.5-3.4) <0.001 
Type of statins      
Simvastatin (C10AA01) 529 (57.0) - - - 
Atorvastatin (C10AA05) 237 (25.5) - - - 
Pravastatin (C10AA03) 96 (10.3) - - - 
Fluvastatin (C10AA04) 66 (7.1) - - - 
Average statin dose, mg     
Simvastatin (C10AA01) 36 - - - 
Atorvastatin (C10AA05) 42 - - - 
Pravastatin (C10AA03) 33 - - - 
Fluvastatin (C10AA04) 54 - - - 
Abbreviations: SD, standard deviation; IQR, interquartile range; HDL-C, high density lipoproteins-cholesterol; 
LDL-C, low density lipoproteins-cholesterol; HOMA-IR, homeostasis model assessment-Insulin resistance 
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Table 2. Multivariate linear regression analysis on the association between statin therapy and serum fasting glucose/insulin 
concentrations and HOMA-IR  
 Crude effect Model 1 Model 2 
Glucose 
concentration 
β coefficient (SEM); 95% CI β coefficient (SEM); 95% CI β coefficient (SEM); 95% CI 
Baseline statin users 0.12 (0.07); -0.02-0.25 0.14 (0.06); 0.04-0.27 0.08 (0.06); -0.03-0.18 
Subgroup analyses    
Statin type    
Simvastatin 0.03 (0.09); -0.14-0.20 -0.01 (0.06); -0.14-0.11 0.01 (0.05); -0.08-0.11 
Atorvastatin -0.10 (0.10); -0.29-0.10 0.02 (0.08); -0.13-0.18 -0.06 (0.06); -0.17-0.06 
Others
* 
Ref   
Statin dose -0.13 (0.07); -0.27-0.01 0.02 (0.06); -0.09-0.14 -0.07 (0.04); -0.16-0.01 
(ln) Insulin 
concentration  
   
Baseline statin users 0.15 (0.02); 0.11-0.20 0.13 (0.03); 0.08-0.19 0.07 (0.03); 0.02-0.13 
Subgroup analyses    
Statin type    
Simvastatin 0.01 (0.04); -0.07-0.09 0.08 (0.05); -0.02-0.18 0.05 (0.05); -0.04-0.15 
Atorvastatin 0.11 (0.05); 0.01-0.20 0.05 (0.06); -0.08-0.17 0.05 (0.06); -0.07-0.16 
Others
*
 Ref   
Statin dose 0.19 (0.03); 0.13-0.25 0.03 (0.05); -0.06-0.12 -0.01 (0.04); -0.09-0.08 
(ln) HOMA-IR     
Baseline statin users 0.19 (0.02); 0.14-0.23 0.16 (0.03); 0.10-0.21 0.09 (0.03); 0.03-0.14 
Subgroup analyses    
Statin type    
Simvastatin 0.01 (0.04); -0.07-0.10 0.08 (0.05); -0.03-0.19 0.05 (0.05); -0.04-0.15 
Atorvastatin 0.10 (0.05); -0.02-0.19 0.04 (0.07); -0.09-0.17 0.04 (0.06); -0.08-0.16 
Others
*
 Ref   
Statin dose 0.19 (0.04); 0.12-0.25 0.03 (0.05); -0.07-0.13 -0.02 (0.05); -0.11-0.07 
Abbreviation: SEM, standard error of the mean; Ln, natural logarithm; CI, confidence interval; HOMA-IR, homeostasis 
model assessment-insulin resistance. 
Model 1 adjusted for age, gender, cohort (I, II and III), smoking status, alcohol consumption, physical activity, and 
education level, and model 2 included all variables in model 1 addition to body mass index and hypertension. 
*
Others including pravastatin and fluvastatin.  
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Table 3. Univariate and multivariate Cox regression analysis on the associations of statin use with 
incident type 2 diabetes  
 
Crude effect: HR; 
95% CI 
Model 1: HR; 95% 
CI 
Model 2: HR; 95% 
CI 
Type 2 diabetes (n=8,844)    
Ever statin users 1.64; 1.37-1.97 1.49; 1.19-1.86 1.38; 1.09-1.74 
Past statin users 1.44; 1.10-1.89 1.20; 0.85-1.68 1.18; 0.83-1.67 
Current statin users 1.63; 1.32-2.02 1.61; 1.23-2.10 1.52; 1.15-2.00 
Subgroup analyses-among 
ever statin users 
   
Statin type    
Simvastatin 0.98; 0.65-1.50 0.92; 0.55-1.53 0.91; 0.54-1.55 
Atorvastatin 1.09; 0.69-1.72 1.50; 0.88-2.56 1.73; 0.99-3.01 
Others
*
 Ref   
Statin dose 1.04; 0.92-1.17 1.02; 0.85-1.23 1.01; 0.79-1.28 
Statin duration    
<30 days 1.04; 0.43-2.51 0.31; 0.04-2.21 0.29; 0.04-2.04 
31-365 2.02; 1.48-2.74 1.66; 1.11-2.49 1.70; 1.13-2.56 
>365 days 1.51; 1.21-1.89 1.51; 1.15-1.98 1.37; 1.04-1.81 
Never statin users Ref   
Abbreviation: HR, hazard ratio; CI, confidence interval  
Model 1 adjusted for age, gender, cohort (I, II and III), smoking status, alcohol consumption, physical 
activity, and education level, and model 2 included all variables in model I addition to body mass index 
and hypertension. 
*
Others including pravastatin and fluvastatin.  
 
 
 
 
 
 
 
 
 
 
Table 4. Sensitivity analyses on the associations of statin ever use with incident type 2 diabetes  
 Model 2: HR; 95% CI 
Excluding cases with impaired fasting glucose at baseline 1.28; 1.00-1.76 
Model 2+TC 1.42; 1.12-1.80 
Model 2+HDL-C, LDL-C and TG 1.26; 0.99-1.61 
Model 2+F.H.D 1.26; 0.98-1.62 
Model 2+ PPIs 1.30; 1.03-1.65 
Model 2+ fasting serum glucose and insulin concentrations  1.41; 1.12-1.78 
Interaction between statin ever use and serum fasting glucose 
concentrations 
3.51; 2.51-4.91 
Abbreviations: HR, hazard ratio; CI, confidence interval; TC, total cholesterol; HDL-C, high 
density lipoproteins-cholesterol; TG, triglycerides; F.H.D, family history of diabetes; PPIs; proton 
pump inhibitors. 
Model 2 adjusted for age, gender, cohort (I, II and III), smoking status, alcohol consumption, 
physical activity, education level, body mass index and hypertension. 
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Fig 1. Flowchart of study population for the current study 
 
 
